Reimagining Druggability

We are reimagining druggability using chemical biology platforms to develop transformative medicines.

Explore more


One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.

Meet Our Team

We are a group of highly motivated scientists with a desire to engage in multidisciplinary research at the interface of chemistry and biology.

Latest News


Our new Lab photo!


Congrats to Nafsika Forte for her paper on covalent recruitment of E2’s for targeted protein degradation

In our latest BioRxiv preprint we discover a covalent recruiter against the E2 ubiquitin conjugating enzymes UBE2D which we use to degrade BRD4 and androgen…

Congrats to Ethan Toriki and James Papaztimas on their discovery of rational chemical design strategies for molecular glue degraders

We posted our BioRxiv preprint on our discovery of a covalent fumarate-based chemical handle that targets RNF126 that can be transplanted onto a broad range…

Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

Financing led by a16z and Deerfield Management with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund Exclusive…

Novartis and UC Berkeley Extend Alliance to Tackle “Undruggable” Disease Targets and Discover New Therapeutic Modalities

July 28th, 2022 Novartis-Berkeley Translational Chemical Biology Institute combines Novartis expertise in chemical biology and medicinal chemistry with Berkeley’s expertise in covalent chemoproteomics and chemistry methodologiesResearch…

Help us advance
our research